As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: January 5, 2020
by Pharmaceutical Technology:
Shanghai Green Valley Pharmaceuticals’ new Alzheimer’s disease drug, Oligomannate, has been conditionally approved in China and became available for purchase in late December. This is the first novel Alzheimer’s disease drug to be approved in almost two decades. While there is global scepticism surrounding the drug’s efficacy, Shanghai Green Valley Pharmaceuticals plans to conduct a multinational clinical trial across North America, Europe, and Asia.
Oligomannate is derived from brown seaweed, and was developed after observations that elderly individuals with high consumption of seaweed demonstrated lower rates of Alzheimer’s disease. Further research published in The Journal Cell Research by scientists at the Shanghai Institute of Materia Medica resulted in the identification of a compound in seaweed that had the ability to reduce both brain inflammation and the buildup of proteins that are harmful to neurons. In Chinese clinical trials, the drug was found to be effective at improving cognitive function in cases of mild to moderate Alzheimer’s disease.
International scientists have considered Oligomannate’s clinical trials to be scant on details. Oligomannate’s efficacy has not yet been compared to that of other Alzheimer’s treatments, and the long-term effects of Oligomannate treatment are currently unknown.
Alzheimer’s disease affects over five million individuals in the US and an estimated ten million individuals in China. Shanghai Green Valley Pharmaceuticals is well-positioned to capitalize on a market with a massive patient pool and little competition, although global clinical trials will be required to prove the utility of Oligomannate as a viable treatment for Alzheimer’s disease beyond China’s borders.
Dementia is a growing problem for people as they age, but it often goes undiagnosed. Now investigators at Harvard-affiliated Massachusetts General Hospital (MGH) and Beth Israel Deaconess Medical Center have discovered and validated a marker of...
While Jeanne Beker may be best known for her work in fashion journalism and television, she’s also an Honourary Board Member of the Women’s Brain Health Initiative (WBHI), a Canadian and U.S. foundation that works to combat brain-aging diseases and protect...
People who experience post-traumatic stress disorder may be twice as likely to have dementia later in life, according to a new study — a finding with important implications for the coronavirus pandemic. The...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.